George Medicines Signs Korea Deal to Commercialize GMRx2
LONDON, UK, March 11, 2026 George Medicines, a late-stage biopharmaceutical company focused on cardiometabolic diseases, has announced an exclusive...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONDON, UK, March 11, 2026 George Medicines, a late-stage biopharmaceutical company focused on cardiometabolic diseases, has announced an exclusive...
Piramal Pharma Solutions, a global contract development and manufacturing organization (CDMO), has collaborated with George Medicines to develop WIDAPLIKâ„¢,...
